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Alzheimer’s disease (AD) is a progressive neurodegenerative disease which 
prevalence is increasing as the population ages. It is the most common cause of 
dementia on elderly and it covers over 60% of all dementias. It is estimated that 
about 33% of over the age of 85 has it. There are two forms of the disease, familial 
and sporadic where familial is rare and sporadic form is generalizing alongside the 
aging population. 
Behind the pathogenesis of AD is altered processing and deposition of two proteins: 
β- amyloid and tau. These proteins accumulate to the brain and cause typical 
pathological changes: amyloid plaques and neurofibrillary tangles that cause 
eventually death of neurons. This leads to progressive decline of cognitive function.          
At this moment, there is no curative or disease- modifying treatment. Only 
symptomatic therapies are available to alleviate some manifestations of the disease.  
Cholinesterase inhibitors are standard first- line drugs used to treat AD. Especially 
dual therapy with NMDA- receptor antagonist memantine show considerable 
improvement in cognitive functions and activities of daily living.  New treatments have 
been developed vigorously over two decades and a lot of time and effort has put on 
targeting β- amyloid. Different compounds affecting its formation, aggregation and 
degradation have developed yet without clinical breakthrough. Effect of sex 
hormones on AD also intrigues researchers and selective sex hormone receptor 
modulators are under investigations. 
AKT also known as protein kinase B is a serine/ threonine kinase that is activated 
downstream mainly by insulin. It regulates many important events such as growth, 
metabolism, proliferation and survival. AKT belongs to the class of AGC- kinases. 
One of its substrates is pro- apoptotic BAD (BCL- 2 associated death protein) which 
is inhibited by phosphorylation by AKT. 
Aim of the study was to investigate whether impaired AKT activation affect on 
phosphorylation of BAD. This was performed by developing a protocol that enables 
best conditions to detect BAD in its phosphorylated state. When conditions were 
balanced, experiments were performed with specific PDK1 K465E- neurons 
developed in the laboratory of Dario R. Alessi. In these neurons AKT activation is 
known to be disrupted. 
The results of the present study indicated that phosphorylation of BAD is impaired in 
PDK1 K465E- neurons. However compared to the earlier findings with other AKT 
substrates results were deviating. Further investigation is needed with PDK1 K465E-
neurons to demonstrate whether BAD phosphorylation is affected or not. 
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Alzheimerin tauti (AT) on progressiivinen neurodegeneratiivinen sairaus jonka 
esiintyvyys kasvaa väestön ikääntyessä. Se on dementian yleisin syy iäkkäillä, 
kattaen yli 60% kaikista dementioista. Arviolta 33% yli 85- vuotiaista sairastaa 
Alzheimerin tautia. Taudista kaksi muotoa: familiaalinen eli perinnöllinen sekä 
sporadinen eli satunnainen. Familiaalinen muoto on harvinainen kun taas sporadinen 
muoto on yleistymässä ikääntyvän väestön rinnalla. 
Alzheimerin taudin patogeneesin aiheuttaa β- amyloidin ja tau- proteiinin häiriintynyt 
prosessointi ja kertyminen aivoihin. Tämä aiheuttaa tyypilliset patologiset muutokset: 
amyloidiplakit ja neurofibrillikimput jotka aiheuttavat lopulta hermosolujen kuoleman. 
Tämä johtaa etenevään kognition heikkenemiseen. Parantavaa tai merkittävästi 
taudin kulkuun vaikuttavaa hoitoa ei vielä ole kehitetty. Olemassaolevat lääkitykset 
ainoastaan helpottavat joitain tautiin liittyviä oireita.  
Antikoliiniesteraasit ovat Alzheimerin taudin hoidon peruslääkkeitä. Erityisesti 
yhdistettynä NMDA- reseptori antagonistiin memantiiniin, lääkkeillä on selkeä 
positiivinen vaikutus kognitioon ja toimintakykyyn. Uusia hoitoja on kehitetty jo yli 
kahden vuosikymmenen ajan mutta toistaiseksi ilman läpimurtoja. β- amyloidien 
muodostumiseen, aggregaatioon ja kertymiseen vaikuttavien lääkkeiden 
kehittäminen on yksi keskeisistä kohteista. Sukupuolihormonien vaikutukset ovat 
myös mielenkiinnon kohteena ja kehityksen alla on selektiivisiä 
sukupuolihormonireseptorien muuntelijoita. 
AKT joka tunnetaan myös nimellä proteiini kinaasi B on insuliinivälitteinen seriini/ 
treoniinikinaasi. Se säätelee monia tärkeitä tapahtumia, kuten solujen kasvua, 
metaboliaa ja selviytymistä. AKT kuuluu AGC- kinaasien luokkaan. Pro- 
apoptoottinen BAD (BCL- 2 associated death protein)- kinaasi on yksi AKT:n 
substraateista. AKT aiheuttaa BAD:in fosforyloitumisen, ja tämä estää sen toimintaa. 
Tutkimuksen tavoitteena oli tutkia onko häiriintyneellä AKT:n aktivaatiolla vaikutusta 
BAD:in fosforylaatioon. Tätä varten määriteltiin parhaat olosuhteet joissa BAD 
voidaan havaita sen fosforyloituneessa muodossa. Tämän jälkeen kokeita suoritettiin 
käyttäen Dario R. Alessin laboratoriossa kehitettyjä PDK1 K465E-  neuroneita, joissa 
AKT aktivaation tiedetään olevan häiriintynyt. 
Suoritetun tutkimuksen perusteella näyttäisi että BAD- kinaasin fosforylaatio on 
alentunut PDK1 K465E- neuroneissa. Kuitenkin, verrattuna aiempiin tuloksiin muiden 
substraattien osalta, tulokset ovat poikkeava. PDK1 K465E- neuroneilla täytyy 
suorittaa lisätutkimuksia jotta yhteys BAD- kinaasin fosforylatioon voidaan vahvistaa.    
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Abbreviations 
 
Aβ β- amyloid 
ACE Angiotensin- converting enzyme 
AD Alzheimer's disease 
AICD Amyloid intracellular domain 
AKT  Protein kinase B (see PKB) 
ApoE  Apolipoprotein E 
APP Amyloid precursor protein 
A1 BCL- 2- related gene A1 
BACE1 β- site APP- cleaving enzyme 1 
BAD BCL- 2 antagonist of cell death/ BCL- 2- associated death protein 
BAX BCL- 2- associated x protein 
BAK BCL- 2 antagonist killer 1 
BBB Blood- brain- barrier 
BCL-2 B- cell CLL/lymphoma- 2 
BDNF Brain- derived neurotrophic factor 
BH BCL- 2 homology domain 
BID BCL- 2- interacting domain death agonist 
BIM BCL- 2- interacting mediator of cell death 
BSA Bovine serum albumin 
CDK5 Cyclin- dependent kinase 5 
ChEI Cholinesterase inhibitors 
CNS Central nervous system 
CT Computed tomography 
DIV Days in vitro 
DLB Dementia with Lewy's bodies 
DMEM Dulbecco’s Modified Eagle’s Medium 
DNA Deoxyribonucleic acid 
ECE Endothelin converting enzyme 
ECL Enhanced chemiluminescence 
ER Endoplasmic reticulum 
ERK2 Extracellular signal- regulated kinase 2 
E15 15th day of pregnancy 
FDA Food and Drug Administration 
6 
 
FOXO Forkhead box transcription factor 
GAP GTPase- activating protein 
GSK3β Glycogen synthase kinase- 3β 
GTP Guanosine triphosphate 
HRP Horseradish peroxidase 
HT Hormone therapy 
IDE Insulin- degrading enzyme 
KRB Krebs Ringer Buffer 
LRP Lipoprotein receptor- related protein 
MAP Microtubule- associated protein 
MCL-1 Myeloid cell leukemia 1 
mLST8 Mammalian lethal with SEC13 protein 8 
MMP9 Matrix metalloproteinase 9 
MMSE Mini- Mental State Examination 
MRI Magnetic resonance imaging 
MT Mutant 
mTOR Mammalian target of rapamycin  
mTORC2 Mammalian target of rapamycin complex 2 
NEP Neprilysin 
NFT Neurofibrillary tangles 
NMDA N- methyl D- aspartate 
NP Neuritic plaques 
NSAID Non- steroidal anti- inflammatory drug 
PDK1 Phosphoinositide- dependent protein kinase- 1 
PI Phosphoinositide 
PIP2 see PtdIns(4,5)P2 
PIP3 see PtdIns(3,4,5)P3 
PI3K Phosphoinositide- 3- kinase 
PKA AMP(adenosine monophosphate)- dependent kinase 
PKB Protein kinase B, also known as AKT 
PKC Ca(Calcium)2+- activated protein kinase 
PKG cGMP (cyclic guanosine monophosphate)- dependent kinase 
PRAS40 Proline- rich AKT substrate 40kDa protein 
PROTOR Protein observed with RICTOR 
PS1  Presenilin 1  
PS2 Presenilin 2 
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PtdIns(3,4,5)P3 Phosphatidylinositol (3,4,5)- trisphosphate 
PtdIns(4,5)P2 Phosphatidylinositol (4,5)- bisphosphate 
RAGE Receptor for advanced glycation end products 
Rheb Ras homology enriched in brain 
RICTOR Rapamycin- insensitive companion of mTOR 
RSK Ribosomal S6 kinase 
SARM Selective androgen receptor modulator 
SDS Sodium dodycyl sulfate 
SDS- PAGE SDS- polyacrylamide- gel electrophoresis 
Ser Serine 
SERM Selective estrogen receptor modulator 
SIN1 SAPK (Stress-activated map kinase)-interacting protein 1 
TSC1 Tuberous sclerosis 1 protein/ hamartin 
TSC2 Tuberous sclerosis 2 protein/ tuberin 
Thr Threonine 
TNFα Tumor necrosis factor α 
WHIMS Women’s Health Iniative Memory Study 
WT Wild type 
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1. Introduction 
 
The most common cause to dementia on elderly is Alzheimer's disease (AD) 
(Knopman 2006, Rinne and Koulu 2007, Färkkilä and Pirttilä 2011, Hong-Qi et al. 
2012). It covers over 60% of all dementias when the percentage of others, for 
example vascular dementias or Dementia with Lewy bodies (DLB) is significantly 
lower. Although AD is sometimes used incorrectly to describe all the dementias in the 
elderly, the disease has its own diagnostic criteria that distinguish it from other forms.  
Clinical diagnosis requires over six months of memory decline accompanied by 
problems with self-care and social or occupational functions (Chu 2012). In most 
cases, family members observe these changes first and seek medical care for 
patient. Accurate diagnosis requires several aspects, including information of family 
history, age, several cognitive tests that measure memory, language skills and 
person’s abilities to function in everyday life. Memory is usually tested with MMSE 
(Mini-Mental State Examination) –test (figure 1) (Yeoman et al. 2006, Chu 2012). 
MMSE scores between 24 and 10 indicate mild-to-moderate AD, respectively and 
scores lower than 10 indicate severe AD. 
It is also important to exclude other brain diseases if they are suspected, by using 
either computed tomography (CT) or magnetic resonance imaging (MRI). There are 
also several other conditions that can cause dementia and must first be ruled out, for 
example hypothyroidism, neurosyphilis, sedation from drugs, chronic heavy metal 
intoxication, human immunodeficiency virus (HIV) infection and Creutzfeldt- Jakob 
disease.  
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Figure 1. MMSE-test is basic tool used in clinical diagnosis of AD to measure 
memory impairment (Yeoman et al. 2006).  
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Clinical characteristics of the disease are progressive disturbances in memory and 
especially in recent memory and in new learning (Knopman 2006, Yiannopoulou and 
Papageorgiou 2013). Deficit in cognition leads to other symptoms including 
disorientation of time and place, impaired judgment and problem- solving and 
disturbances of language skills. These key manifestations of AD are typically 
followed by varying neuropsychiatric symptoms such as depression, agitation and 
sleep disturbances. Progression of the disease lead eventually to death, depending 
of the individual in nine to twelve years from onset of symptoms (Knopman 2006). 
Some approximate milestones of AD are shown in the figure 2. 
 
 
Figure 2. Progression of Alzheimer's disease (Knopman 2006). 
 
 
14 
 
It was estimated that in 2007 in Finland 100 000 people had moderate or severe AD 
(Färkkilä and Pirttilä 2011). The prevalence of AD correlates with advancing age 
(Knopman 2006, Rinne and Koulu 2007, Färkkilä and Pirttilä 2011, Gauthier et al. 
2012, Hong-Qi et al. 2012, Povova et al. 2012). AD is rare under the age of 60 
whereas it is estimated that 20- 50% of over the age of 85 has it. As the population 
ages, the prevalence of AD grows. It is believed that the prevalence doubles every 
20 years. Everyone has the major risk factor: age, if living long enough. 
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2. Etiology 
 
Two forms of the disease have been recognized, familial and sporadic Alzheimer's 
disease (Lippa et al. 1996, Knopman 2006). There are three genes that have been 
implicated in familial forms of AD: amyloid precursor protein (APP), presenilin- 1 
(PS1) and presenilin- 2 (PS2) and they all are autosomal dominant genes (Selkoe 
1999, Knopman 2006, Chu 2012). Mutations in APP, PS1 or PS2 gene favors 
formation of amyloidogenic Aβ- peptides by β- and γ- secretases (see chapter 3.1.) 
(Kimberly et al. 2000, Hardy and Selkoe 2002). Especially mutation in PS1 gene, 
which is the catalytic core of γ- secretase, increases Aβ42: Aβ40 ratio (Placanica et al. 
2009).  
Inheritance of one or two alleles of susceptibility gene apolipoprotein E (ApoE), also 
increases the risk for developing AD in both forms of the disease.  
Familial and sporadic forms of the disease lead to same end point and share same 
pathologic features, although in familial form onset of symptoms happen on earlier 
age and histological changes are more severe (Lippa et al.1996). However, familial 
AD is rare (Chu 2012). Approximately 15% of AD patients have family history of the 
disease.  
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3. Pathophysiology 
 
The key event in pathogenesis of AD is altered processing and deposition of two 
proteins: β- amyloid (Aβ) and tau (Knopman 2006, Querfurth and LaFerla 2010, 
Apostolova et al. 2012). Accumulation of these proteins to the brain leads to 
dysfunction and eventually to death of neurons. Other pathological features are 
amyloid angiopathy, oxidative and inflammatory damage and loss of white matter due 
to the loss of axons. 
Typical areas in the brain where atrophy can be detected in AD patients are cortex 
and hippocampus, accompanied with enlargement of cerebral ventricles (Apostolova 
et al. 2012). Some of these features are associated with normal aging, but with far 
slower progression rate. Atrophy has an impact especially on cholinergic system 
(figure 3), starting from basal forebrain and leading to cortex and limbic areas of the 
brain (Farlow 2002). This leads to progressive loss of acetylcholine neurons and 
impaired production and degradation of acetylcholine (Chu 2012, Yiannipoulou and 
Papageorgiou 2013). Loss of cholinergic activity correlates with cognitive 
dysfunction, and it declines as the disease progress (Farlow 2002). 
 
 
Figure 3. Cholinergic system in the brain (Revised from Newman et al. 2012). 
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Progressive atrophy involves also other neurotransmitter systems, for example it 
causes imbalance in monoamine and excitatory amino acid systems (Farlow 2002). 
One important neurotransmitter that is affected is glutamate. Glutamate is excitatory 
neurotransmitter that mediates learning and memory in pyramidal cells in the 
hippocampus and cortex via N-methyl D-aspartate (NMDA) receptors (Chu 2012). 
Although an excess amount of glutamate is detrimental and it is associated with 
neurotoxicity. 
 
3.1 Formation of neuritic plaques (NP) 
APP is cleaved by three secretases, α, β and γ (Kimberly et al. 2000, Knopman 2006, 
Querfurth and LaFerla 2010, Hong-Qi et al. 2012, Yiannopoulou and Papageorgiou 
2013). Aβ- peptides are natural metabolic end products deprived by β- secretase, 
also named  β-site APP- cleaving enzyme 1 (BACE1), and γ-secretase. β- and γ- 
secretase are responsible for formation of amyloidogenic peptides and α- secretase 
proteolysis leads to formation of nonamyloidogenic end products (figure 4). 
Localization of amyloid precursor protein (APP) to chromosome 21 was supported by 
the earlier findings that Down's syndrome (trisomy 21) has link with AD (Hardy and 
Selkoe 2002, Knopman 2006). It was found that possessing extra chromosome 21 
with the APP gene accelerated the pathology of AD (even 30 years) in Down's 
syndrome patients.   
Aβ- peptides consist of 36 to 43 amino acids and corresponding to the major cleaving 
sites of γ- secretase (Kimberly et al. 2000, Knopman 2006, Querfurth and LaFerla 
2010, Hong-Qi et al. 2012, Yiannopoulou and Papageorgiou 2013). Aβ40 and Aβ42 
are the most common forms. Aβ42 species are found to be the most harmfull due to 
its tendency to aggregate into fibrils and thus trigger the formation of neuritic plaques 
(Tanzi and Bertram 2005). As the figure 5 shows, first phases of the amyloid cascade 
hypothesis comprise of overproduction and accumulation of Aβ and formation of 
plaques, leading progressively to dementia (Hardy and Selkoe 2002). 
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Figure 4: Processing of Amyloid Precursor Protein (Revised from Hong-Qi et al. 
2012). AICD = amyloid intracellular domain 
 
Several researches reveal that the total amount of amyloid plaques found post-
mortem from the AD patients' brain does not always correlate to the severity of the 
disease (Querfurth and LaFerla 2010, Selkoe 2011). Still it is belived that among 
individuals who possess mutations in APP or presenilin genes, the causative reason 
for AD is accumulation and aggregation of Aβ42 (Selkoe 2011). 
Rising of the Aβ monomer levels caused by several reasons, slowly leads to 
formation of dimers and then larger oligomers (Selkoe 2011). With time, these 
molecules start to form progressively growing fibrils with a tendency to bind cell 
membranes. This event temporarily decreases the amount of free particles in the 
brain and thus can be seen as protective phase. As the disease progress, fibrils 
develop to plaques eventually reaching maximal size and density, allowing increasing 
amount of oligomers to remain free to cause synaptic/ neuritic injury to surrounding 
cells. So the combined effect of neuritic plaques and free diffusible oligomers are the 
cause of Aβ induced neuronal death. 
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Figure 5. Amyloid cascade hypothesis (Hardy and Selkoe 2002). 
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3.2 Formation of neurofibrillary tangles (NFT) 
Tau is a microtubule- associated protein (MAP) that resides mainly in the axons 
(Querfurth and LaFerla 2010, Duan et al. 2012). In normal conditions it is a soluble 
protein which is controlled by balance between phosphorylation and 
dephosphorylation. The primary function of tau is to maintain stability of microtubules 
and it is also responsible for the transport of signalling molecules, trophic factors and 
other essential cellular constituents (for example mitochondrias and vesicles) along 
the axons.  
When dephosphorylation is impaired, tau becomes hyperphosphorylated by several 
serine/ threonine kinases and amount of free tau fraction is elevated (Duan et al. 
2012). When tau is hyperphosphorylated it becomes insoluble and it detaches from 
microtubules. Hyperfosforylated tau form pretangles (nonfibrillary tau deposits), 
paired helical filaments and finally combination of these leads to formation of 
neurofibrillary tangles (NFTs).  
Several kinases responsible for tau phosphorylation have been suggested, for 
example insulin- mediated AKT substrate glycogen synthase kinase 3β (GSK3β) (see 
II EXPERIMENTAL PART chapter 6.3.3.), cyclin- dependent kinase 5, (CDK5) and 
extracellular signal- regulated kinase 2 (ERK2) (Zhao and Townsend 2009, Duan et 
al. 2012, Hong-Qi et al. 2012, Tokutake et al. 2012, Yiannopoulou and Papageorgiou 
2013). ). If AKT signaling is impaired, it is reflected by weakened inhibition of GSK3β. 
This leads to overactivation of GSK3β and thus to hyperphosphorylation of tau (Zhao 
and Townsend 2009). Controlling the overactivity of these kinases may show 
potential in disease-modifying therapies in the future. 
 
3.3 Synergism of Aβ and tau 
Connection between Aβ and tau is not yet fully elucidated, but it is believed that 
accumulation of Aβ initiates tau hyperphosphorylation and vice versa, tau can 
mediate Aβ toxicity (Querfurth and LaFerla 2010, Duan et al. 2012, Parthsarathy et 
al. 2013). According to the research made by Götz et al. (2001), Aβ42 fibrils enhance 
NFT formation in vivo supporting the hypothesis that causative factor to pathogenesis 
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is Aβ. Furthermore in the research of Tokutake and coworkers (2012) was suggested 
that elevated Aβ- levels in the AD brain disrupt the insulin- PI3- AKT signaling (see 
chapter 6.2.) which leads to tau hyperfosforylation by GSK3β. On the other hand, the 
research of Rapoport et al. (2002) provides evidence that tau has a key role in the 
mechanism that leads to fibrillar Aβ- deposits.  
 
3.4 Toxic effects of microglia 
Microglias are considered as brain's macrophages (Venneti et al. 2009, Rosenberg 
2005). They are important immune cells capable of phagocytosis and antigen 
presentation. They become activated by several factors that pose a potential threat to 
homeostasis of the brain. One of those factors is Aβ (Rogers et al. 2002, Rosenberg 
2005). Accumulation of Aβ initiates inflammation and neurotoxic process (Selkoe 
1999).  
Aβ-plaques attract microglia to their vicinity where they become activated. Activated 
microglia has ability to phagocytose Aβ-plaques, and interestingly estrogen is found 
to increase this ability (Rogers et al. 2002, Rosenberg 2005). Microglia also produce 
cytokines, neurotoxins and some proteolytic enzymes that degrade Aβ, such as IDE 
(insulin-degrading enzyme), NEP (neprilysin), MMP9 (matrix metalloproteinase 9) 
and plasminogen.  
The role of microglia in AD pathogenesis is controversial (Venneti et al. 2009). It is 
known that microglia are capable to phagocytose amyloid plaques and soluble Aβ 
and therefore enhance amyloid clearance (Rogers et al. 2002, Venneti et al. 2009). It 
has also been demonstrated that microglia have important role of promoting adult 
neurogenesis. It is normal that neurogenesis declines with age, but it is especially 
disrupted with AD patients. 
Taken these protective mechanisms together a question arises: what causes 
microglia to change from anti-inflammatory/ neuroprotective to pro-inflammatory/ 
neurotoxic mediators? 
The research made by Hickman et al. (2008) indicates that microglia become 
dysfunctional as the disease progress and the Aβ load increases. Due to the 
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reduction of Aβ- binding receptors microglia lose the ability to phagocytose Aβ and 
also production of Aβ- degrading enzymes reduces significantly. However, the ability 
to produce pro- inflammatory cytokines maintains. Interestingly, cytokines have been 
found to be responsible of reduction of Aβ- binding receptors and reduced expression 
of proteolytic enzymes. It has also been found that the main cytokines produced by 
microglia, TNFα (tumor necrosis factor α) and several others, stimulate β- secretase 
(BACE1) and γ- mediated cleavage of APP therefore increasing the Aβ load even 
further.  
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4. Current therapies 
 
Despite of decades of active research, there is still no curative treatment for AD 
(Hong-Qi et al. 2012, Huang and Mucke 2012, Yiannopoulou and Papageorgiou 
2012). According to the figure 5 and generally accepted theory, the accumulation of 
Aβ is the key event in AD pathogenesis. Thus a lot of time and effort have been 
spent to develop therapeutics that reduce Aβ load in the brain (Ghosh et al. 2012).  
Overall, there are several potential steps in the pathogenesis of AD that could be 
targeted with therapies (Hardy and Selkoe 2002, Huang and Mucke 2012, 
Yiannopoulou and Papageorgiou 2013). In addition to Aβ accumulation and NFTs, 
also inflammation, oxidative damage, deregulation of metals, mitochondrial 
impairments and cholesterol metabolism are responsible of development of clinical 
symptoms.  
All current treatments to Alzheimer’s disease are symptomatic neutransmitter 
enhacement therapies (Chu 2012, Yiannopoulou and Papageorgiou 2013). They do 
not modify or stop the course of the disease but they alleviate symptoms and 
perhaps postpone institutionalization of an individual.  
 
4.5 Cholinesterase inhibitors (ChEIs) 
Cholinesterase inhibitors prolong availability and activity of acetylcholine in the 
synaptic cleft by reducing its hydrolysis by acetylcholinesterase (and additionally 
butyrylcholinesterase by rivastigmine) (Farlow 2002, Chu 2012). First ChEI approved 
by U.S. Food and Drug Administration (FDA) for AD was tacrine in 1993 but it is not 
used anymore due to hepatotoxicity (Farlow 2002, Chu 2012, Hong- Qi et al.2012, 
Yiannopoulou and Papageorgiou 2013). Currently there are three cholinesterase 
inhibitors (ChEIs) approved for clinical use of mild to moderate AD (MMSE between 
24-10; figure 1): donepezil, rivastigmine and galantamine (approved by FDA in 1996, 
2000 and 2001, respectively). Donepezil has later approved also for the treatment of 
severe AD (MMSE <10; figure 1) in the USA. 
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ChEIs are standard first-line drugs used to treat AD (table 1). Several reviews and 
meta-analyses indicate improvement in cognitive functions and MMSE scores over 
the first three months with ChEI use compared to placebo. Also long-term treatments 
(up to five years) have showed delayed decline in cognitive functions and activity of 
daily living. 
 
Table 1. Current therapies used in AD. (Revised from Chu 2012, Pharmaca Fennica 
2013). 
Drug Class Dosage form 
Dose 
(mg/day) 
Frequency 
(times/day) 
Metabolism 
Donepezil ChEI Oral 5-10 1 
CYP2D6 
CYP3A4 
Galantamine ChEI Oral 8-24 1* 
CYP2D6 
CYP3A4 
Rivastigmine ChEI 
Oral, 
transdermal 
patch 
3-12 2** Non-hepatic 
Memantine 
NMDA-
receptor 
antagonist 
Oral 5-20 2 Non-hepatic 
* When used prolonged-release formulation 
** With transdermal patch change once a day  
 
Generally ChEIs are well tolerated (Chu 2012). Typical adverse events of ChEIs are 
gastro-intestinal, such as nausea, vomiting, diarrhea and abdominal cramp (Chu 
2012, Yiannopoulou and Papageorgiou 2013). Systemic reviews suggests that the 
incidence is lower with donepezil that with rivastigmine and galantamine. Adverse 
events are more common with higher therapeutic doses and during dose escalation. 
Therefore slow titration upwards is in key role when starting ChEI treatment. Table 1 
shows starting- maximum doses of each ChEI.  As table 1 indicates, all ChEIs are 
available in oral forms, but only rivastigmine has transdermal patch formulation. Use 
of transdermal rivastigmine minimizes gastro-intestinal adverse events, so it is good 
option for oral formulations especially if patient suffers from intense side effects. 
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Comparison of efficacy between ChEIs is poorly documented and limited evidence 
exists (Chu 2012). If a patient does not respond to one ChEI, there is an option of 
switching to an alternate ChEI with a different pharmacologic profile (Farlow 2002). 
Especially if patient is treated unsuccessfully with selective acetylcholinesterase 
inhibitor (donepezil or galantamine) may benefit of switching to rivastigmine which is 
dual inhibitor of acetyl- and butyrylcholinesterase. 
 
4.6 N-methyl-D-aspartate (NMDA) antagonist 
Moderate- affinity non- competitive, NMDA- type receptor antagonist memantine was 
approved for treatment of moderate to severe AD by FDA in 2003 (Chu 2012, Hong-
Qi et al. 2012, Yiannopoulou and Papageorgiou 2013). As the disease progress, 
other neurotransmitter systems are also affected (see chapter 3.) and excess amount 
of glutamate is present. Memantine is believed to protect neurons from glutamate 
induced excitotoxicity while maintaining normal concentration of glutamate needed 
on learning and memory functions. 
Clinical trials have shown beneficial effects of memantine compared to placebo on 
cognition, behavior and activity of daily living (Chu 2012, Hong-Qi etc. 2012, 
Yiannopoulou and Papageorgiou 2013). Use of memantine indeed alleviates 
deterioration of mood, agitation, irritability or delusions.  
Memantine treatment is recommended to start with the dose 5 mg once a day (Chu 
2012). After this it is increased weekly by 5 mg up to maximum daily dosage of 20 
mg. Overall memantine is well tolerated. Putative adverse events are hardly more 
common compared to placebo-treated patients. Dizziness, confusion, hallucinations, 
head ache, somnolence and nausea are the most common adverse events reported 
(Chu 2012, Yiannopoulou and Papageorgiou 2013). 
Dual therapy with memantine and donepezil with moderate or severe AD patients 
have shown considerable improvement in cognitive and functional outcomes, activity 
of daily living and behavior compared with placebo group (memantine and placebo) 
(Hong-Qi et al.2012, Yiannopoulou and Papageorgiou 2013).  
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5. Future therapies 
 
 
5.1 Targeting Aβ 
As it is known, Aβ is a neurotoxin and its accumulation to the brain leads to oxidative 
stress and neuronal dysfunction and destruction (Hong-Qi et al. 2012). Preventing 
formation and accumulation of Aβ in the brain is in the key role on the road to 
developing therapeutics. 
 
5.1.1 Formation 
 
β- and γ- secretases, which are responsible of Aβ- formation, are interesting targets 
of drug design (Hardy and Selkoe 2002, Tanzi and Bertram 2005, Hong- Qi et al. 
2012, Huang and Mucke 2012, Yiannopoulou and Papageorgiou 2013). One 
therapeutic approach could be inhibiting these secretases and thus prevent 
excessive Aβ- formation. However, development of β- and γ- secretase inhibitors has 
faced many problems including a weak bioavailability, a poor blood- brain- barrier 
(BBB)- penetration and difficult side effects.  
Typical problems with β- and γ- secretase inhibitors are detrimental side effects, 
because their diverse regulation of other substrates (Hardy and Selkoe 2002, Tanzi 
and Bertram 2005, Hong- Qi et al. 2012, Huang and Mucke 2012, Yiannopoulou and 
Papageorgiou 2013). One γ- secretase substrate is Notch receptor 1, an important 
protein involved in growth and development. Inhibition of Notch leads to severe 
gastrointestinal and hemopoetic side effects and this has been an obstacle 
hampering the development of clinically potent γ- secretase inhibitor.  
Complications encountered with BACE1 inhibitors mostly result from inadequate 
BBB- penetration (Hardy and Selkoe 2002, Tanzi and Bertram 2005, Hong- Qi et al. 
2012, Huang and Mucke 2012, Yiannopoulou and Papageorgiou 2013). The drugs 
developed have been mostly small peptides that have to be administered directly to 
the brain to achieve effects and therefore their clinical use seems unpromising. 
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Two γ- secretase inhibitors have made to the phase III trials but failed: a putative γ- 
secretase modulator R- flurbiprofen/ tarenflurbil derived from a NSAID (non- steroidal 
anti- inflammatory drug) and γ- secretase inhibitor semagestat (LY- 450139) (Selkoe 
2011, Hong-Qi et al. 2012, Yiannopoulou and Papageorgiou 2013). Setbacks were 
due to a low efficacy, a poor brain penetration and severe side effects, respectively. 
 
5.1.2 Clearance and degradation 
 
One reason for elevated Aβ levels in the brain is impaired clearance and degradation 
of Aβ (Tanzi and Bertram 2005, Hong-Qi et al. 2012). Low- density lipoprotein 
receptor- related protein (LRP) plays a key role in exporting Aβ from the brain. If the 
function of LRP is impaired it reduces Aβ clearance substantially. It has been found 
that in AD patients LRP activity is lowered (Tanzi and Bertram 2005). In contrast a 
protein responsible for transporting Aβ in to the brain (the receptor for advanced 
glycation end products/ RAGE) has become more active in AD patients. Affecting to 
the balance between these transporters may show therapeutic potential, but no 
clinical data is yet available. 
Major degrading enzymes that participate in Aβ clearance are neprilysin (NEP) and 
insulin degrading enzyme (IDE) (Tanzi and Bertram 2005, Querfurth and LaFerla 
2010, Hong-Qi et al. 2012). Animal models have shown that inhibition of these 
enzymes decrease Aβ degradation and decline cognitive activity (Hong-Qi et al. 
2012). Also endothelin converting enzyme (ECE), 1 and 2 angiotensin- converting 
enzyme (ACE) and plasminogen system have the ability to degrade the Aβ- peptide 
at different amino acid residues within the Aβ sequence.  
 
5.2 Sex hormones 
Female sex steroid hormones are mainly produced in the ovary but it has been 
demonstrated that also glial cells and neurons are capable of producing them in 
several regions in the central nervous system (CNS) and especially in the 
hippocampus (Carroll and Rosario 2012).  
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Estrogens and androgens (male sex steroid hormones) are found to be 
neuroprotective agents and they promote neural viability and facilitate synaptic 
plasticity in the brain (Barron and Pike 2012, Carroll and Rosario, Hong-Qi et al. 
2012). It has been demonstrated that estrogens and androgens regulate production 
and clearance of Aβ, and they also reduce Aβ levels in the brain (Barron and Pike 
2012). Therefore it has been hypothesized that age- related loss of these hormones, 
especially with post- menopausal women, represents an important risk-factor to AD.  
 
Figure 6. A schematic view of different risk factors affecting AD, and possible sex 
hormone- based therapies (Barron and Pike 2012). 
SARM/ SERM = Selective Androgen/ Estrogen Receptor Modulator 
 
Similar to the estrogen, age- related testosterone loss in men is also connected with 
the increased risk of developing AD (Carroll and Rosario 2012). Although 
testosterone levels decrease along with age, there is a deal of variability among 
individuals. Androgens have several beneficial actions in the brain, which is a highly 
androgen- responsive tissue. Older men with high levels of free circulating 
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testosterone have shown to exhibit better long- term memory (Carroll and Rosario 
2012). 
Results of hormone replacement therapies in the treatment of AD are controversial. 
Some researches indicate that hormone therapies have therapeutic efficacy by 
improving memory and cognition in older postmenopausal women with AD (Wharton 
et al. 2011). However, Women’s Health Initiative Memory Study (WHIMS) done by 
Shumaker et al. (2003, 2004) indicates that hormone therapy by using estrogen plus 
progestin or estrogen alone increases the risk of dementia and impairment of 
cognition. Hormone replacement therapy use is also associated with adverse events, 
such as promoting cancers in reproductive tissues or in breasts (Shumaker et al. 
2003, Barron and Pike 2012, Carroll and Rosario 2012).  
Hormone replacement therapy is rare with men, although it is estimated that 30%- 
70% of men over 70 years in the U.S. suffers from androgen deficiency (Carroll and 
Rosario 2012). Hormone replacement therapy in preventing cognitive decline in 
aging men is far less studied compared to post- menopausal women. Few results of 
efficacy of hormone replacement therapy use in treating and or preventing AD in 
aged men provide mixed results. As with estrogen- based therapy of aging women, 
risks linked with testosterone therapy include different cancers, atherosclerosis and 
hypertension. 
Now efforts has been targeted to develop selective estrogen and androgen receptor 
modulators (SERM and SARM) that are able to penetrate BBB, has neuroprotective 
effects and do not have receptor- dependent effects on other hormonal tissues 
(breasts, uterus, prostate) (Carroll and Rosario 2012).  
As figure 7 shows, sex hormones and especially androgen has many beneficial 
effects related to AD pathogenesis. Targeting these mechanisms with proper SARMs 
may turn out as future therapy in reducing the risk of AD in aging men. 
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Figure 7. Many effects of sex hormones (Carroll and Rosario 2012). Androgen is 
known to mediate many pathways related to AD by: 1. increasing neuronal viability 
via promoting phosphorylation of pro- apoptotic kinase Bad (see II EXPERIMENTAL 
PART chapter 6.5.3.) 2. decreasing Aβ- levels by inducing degrading enzyme 
neprilysin (NEP) and 3. decreasing tau hyperphosphorylation by inhibiting GSK3β 
(see II EXPERIMENTAL PART chapter 6.3.3.). 
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II EXPERIMENTAL PART: 
Effect of impaired AKT function on phosphorylation 
of pro- apoptotic BAD 
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6. Introduction 
 
6.1. AKT 
 
Protein kinase B (PKB) also known as AKT (figure 8), is a serine/threonine protein 
kinase that mediates many important downstream events regulated by 
phosphoinositide-3-kinase (PI3K) (Lawlor and Alessi 2001). Akt gene family has 
three members named as AKT1 (PKBα), AKT2 (PKBβ) and AKT3 (PKBγ) (Bellacosa 
et al. 2004). Tissue distribution of different members varies, where AKT1 and AKT2 
are expressed ubiquitously while AKT3 is mainly found in neuronal tissues. 
AKT family belongs to the class of AGC kinases. This name comes from the 
members of the family, namely AMP-dependent kinase (PKA), cGMP-dependent 
kinase (PKG) and Ca2+-activated protein kinase (PKC) as well as phosphoinositide-
dependent protein kinase-1 (PDK1) (Lawlor and Alessi 2001, Parker and Parkinson 
2001, Hanada et al. 2004). All of these protein kinases are activated and regulated 
by small second messengers such as cyclic mononucleotides, Ca2+ or 
phosphoinositides.  
All three AKT isoforms share a similar structure (Hanada et al. 2004, Vasudevan and 
Garraway 2010). They consist of different functional domains including an amino 
terminal pleckstrin homology (PH) domain, a central kinase domain and the 
hydrophobic motif, a carboxyl-terminal regulatory domain that is a representative of 
AGC kinase-family. 
 
6.2. Activation of AKT 
 
AKT is activated downstream by the phosphoinositide-3-kinase (PI3K), in response 
to growth factors, cytokines and hormones such as insulin (Figure 8) (Lawlor and 
Alessi 2001, Bellacosa et al. 2004, Pearce et al. 2010, Vasudevan and Garraway 
2010). After PI3K is recruited to the plasma membrane and activated, it 
phosphorylates 3´-OH position in the inositol phospholipids to 3´-phosphoinositides 
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(PIs) (Vivanco and Sawyers 2002). These important second messengers generated 
by PI3K are called phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5) P2 or PIP2)) 
and phosphatidylinositol (3,4,5)- trisphosphate (PtdIns(3,4,5)P3 or PIP3). 
PH is the domain in the N-terminal region of AKT that interacts with second 
messengers PIP2 and especially with PIP3 (Bellacosa et al. 2005, Hennessy et al. 
2005). This event contributes to the recruitment of AKT to the plasma membrane and 
triggers a conformational change that is vital for phosphorylation at two main amino 
acid residues of AKT.  
 
 
 
One activating residue is threonine- 308, and it resides in the central kinase domain 
(Sarbassov et al. 2005, Vasudevan and Garraway 2010, Hers et al. 2011). Thr- 308 
phosphorylation occurs via phosphoinositide- dependent protein kinase- 1 (PDK1). 
PDK1 can phosphorylate itself at position Ser-241 leading to its activation 
Figure 8. Phosphorylation of AKT (Pearce et al. 2010). 
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(Casamayor et al. 1999). As well as its substrate AKT, PDK1 contains PH domain 
which interaction with PIP3 and to a lesser extend with PIP2 is crucial in order to co- 
localize with AKT and phosphorylate it (Anderson et al. 1998, Currie et al. 1999, 
Bayascas et al. 2008). This leads to partial activation, but phosphorylation of both 
residues is vital to generate high activity of AKT (Alessi et al. 1996, Pearce et al. 
2010). 
The other activating residue is at position serine 473 in AKT1 and it is located in the 
C-terminal hydrophobic domain. The identity of the kinase responsible for Ser- 473 
phosphorylation remained elusive for long time after the Thr- 308 kinase was already 
discovered (Vasudevan and Garraway 2010). Now it is known that Ser- 473 is 
phosphorylated by a complex named mTORC2 (mammalian target of rapamycin 
complex 2) (Figure 8) that consists of mTOR (mammalian target of rapamycin), 
mLST8 (mammalian lethal with SEC13 protein 8), RICTOR (rapamycin- insensitive 
companion of mTOR), SIN1 (SAPK- interacting protein 1) and PROTOR (protein 
observed with RICTOR) (Guertin and Sabatini 2007). Phosphorylation of AKT does 
not happen if some of the genes encoding mTOR interacting proteins that define 
mTORC2 (RICTOR, mLST8 or SIN1) is deleted. This finding supports strongly the 
claim that AKT is directly regulated via mTORC2. 
 
6.3. AKT substrates 
 
6.3.1. TSC2 
 
One of the many functions that AKT regulates (figure 9) is cell growth and protein 
translation through the TSC2/mTORC1 pathway (figure 10) (Vasudevan and 
Garraway 2010). Tuberous sclerosis 2 protein (TSC2, also known as tuberin) forms a 
heterodimeric complex with TSC1 (also known as hamartin) and  they both together 
suppress mTORC1 activity (Bellacosa et al. 2004, Guertin and Sabatini 2007, 
Manning and Cantley 2007, Vasudevan and Garraway 2010). When TSC2 is 
phosphorylated by AKT, the TSC1/TSC2- complex GAP (GTPase- activating protein) 
activity is inhibited allowing Rheb (Ras homolog enriched in brain) binding to GTP. 
As a result, formed GTP-Rheb complex causes mTORC1 activation. 
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Figure 9. AKT and its many substrates (Manning and Cantley 2007). 
 
Figure 10.  AKT mediated regulation of TSC2 and PRAS40 (Guertin and Sabatini 
2007). 
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6.3.2. PRAS40 
 
Proline-rich AKT substrate 40kDa protein (PRAS40) is phosphorylated by AKT on 
Thr246 (Manning and Cantley 2007, Vasudevan and Garraway 2010, McCubrey et 
al. 2012, Wiza et al. 2012). In the steady state PRAS40 inhibits mTORC1 activity 
through direct protein-protein interaction. When AKT itself becomes activated in 
response to insulin (figure 8), it phosphorylates PRAS40 on Thr246 causing relieve of 
its inhibitory action on mTORC1 (figure 10). Phosphorylation of PRAS40 enhances 
its binding to 14-3-3 proteins and vice versa weakens its interaction with mTORC1 
enabling its activation. 14-3-3 proteins are important regulators of many client 
proteins by binding them and thus controlling many physiological and pathological 
processes (Zhao et al. 2011). 
 
6.3.3. GSK3 
 
Glycogen synthase kinase- 3 (GSK3) is important metabolic kinase that was found 
over 30 years ago (Embi et al. 1980). It was the first direct AKT substrate indentified 
(Cross et al. 1995). It regulates glucose and lipid metabolism (Manning and Cantley 
2009) and it has role in Wnt-signalling pathway that is in essential role in embryonic 
development (Frame and Cohen 2001). Insulin is a GSK3 inhibitor through AKT- 
pathway. AKT phosphorylates GSK3 in its N- terminal serine residue and 
phosphorylation leads to GSK3 inactivation (Frame and Cohen 2001, Bellacosa et al. 
2004, Manning and Cantley 2009).  
 
6.3.4. FOXO 
 
The forkhead box transcription factors (FOXO) resides in the nucleus in the absence 
of survival stimuli (Harris 2003, Chong et al. 2005, Manning and Cantley 2009, 
Vasudevan and Garraway 2010). Forkhead family mediates apoptosis, cell-cycle 
arrest and metabolic processes by inducing expression of many pro-apoptotic and 
cell- cycle inhibitory factors. Three members have been identified (FOXO1, FOXO3a 
and FOXO4) and all of them can be phosphorylated by AKT. Phosphorylation by AKT 
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leads to their export from the nucleus to the cytosol. Once in cytosol they interact 
with 14-3-3 proteins ( Zhao et al. 2011) and their transcription of cell- death targets is 
blocked. 
 
6.3.5. BAD 
 
BAD (BCL- 2 antagonist of cell death/ BCL- 2- associated death protein) is a pro- 
apoptotic member of BCL- 2 (B cell CLL/lymphoma- 2) protein family (Yang et al. 
1995, Adams and Cory 1998, Datta et al. 2000, Henshall et al. 2002, Chipuk et al. 
2010). Family of BCL- 2 comprises of pro-survival and pro-apoptotic proteins and 
expression of them varies between different cells. BCL- 2 proteins play key role in 
controlling outer mitochondrial membrane integrity and apoptosis. Through a 
complex interaction between members, they regulate balance between survival and 
commitment to apoptosis. They have functions also in numerous cellular pathways 
for example in mitochondrial dynamics and endoplasmic reticulum (ER) calcium 
storage. 
Major pro-survival members of this family (Figure 11) are: BCL- 2, long isoform (BCL- 
XL), BCL- w, myeloid cell leukemia 1 (MCL- 1) and BCL- 2-related gene A1 (A1). 
BCL- 2 and BCL- XL antagonize BAD so the focus will be on these two members in 
my thesis.   
Pro-apoptotic members include proteins such as BAX (BCL-2-associated x protein), 
BAK (BCL-2 antagonist killer 1), BID (BCL- 2- interacting domain death agonist), BIM 
(BCL- 2- interacting mediator of cell death) and BAD (Figure 10& 11) (Adams and 
Cory 1998, Datta et al. 2000, Chipuk et al. 2010).  
A conserved trait of the structure of this family members is possessing at least one of 
the four different conserved motifs called BCL- 2 homology domains (BH1- BH4) 
(Figure 11). 
BAD is a distant member of this family because of its divergent structure. It contains 
only one of the homology domains: BH3, also known as the minimum death domain 
(Danial 2009). BH3- proteins are still subdivided in two classes depending on their 
ability to interact with other BCL- 2 family members; can they work independently or 
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do they bind to others and work as “sensitizators” and/or “de- repressors” (Chipuk et 
al. 2010). 
BAD belongs to the latter group because it cannot work as an apoptotic factor 
independently but in order to promote apoptosis, it has to form a complex with pro-
survival BCL- 2, BCL- XL or BCL- w (Yang et al. 1995, Datta et al. 2000, Chipuk et al. 
2010).  In the case of BCL- XL it is known that interaction with BAD happens through 
the interface formed between hydrophobic cleft of the BCL- XL and the hydrophobic 
face of the amphipatic BH3 domain of BAD (Datta et al. 2000).  A protective function 
of BCL- 2 or BCL- XL is abolished when a tightly bound heterodimer with BAD is 
formed (Yang et al. 1995, Zha et al. 1996, Datta et al. 2000, Miyawaki et al. 2008).     
In the absence of survival stimuli BAD works as de-repressor by replacing pro-
apoptotic member BAX from heterodimer- complex with BCL- 2 or BCL- XL and in this 
way causes release of BAX. Release of pro-apoptotic BAX proceeds towards 
mitochondrial outer membrane permeabilization, caspase activation and finally 
apoptosis (Yang et al. 1995, Henshall et al. 2002, Chipuk et al. 2010).  
In the presence of survival stimuli BAD is at phosphorylated state and it is located in 
the cytosol bound with 14-3-3 protein (Zha et al. 1996, Datta et al. 2000, Zhao et al. 
2011). BAD has three phosphorylation sites: Ser- 112, Ser- 136 and Ser- 155. AKT 
primarily phosphorylates BAD at Ser- 136 and it may have part in Ser- 112 
phosphorylation as well (Datta et al. 1997). Still phosphorylation of Ser- 136 alone 
promotes survival by improving 14-3-3 docking (Datta et al. 2000, Danial 2009). Ser- 
136 phosphorylation leads to phosphorylation of Ser- 155 that is crucial in order to 
inhibit formation of heterodimer with BCL- XL. Ser- 155 is located on the BH3- domain 
that interacts with hydrophobic groove of the pro-survival family members such as 
BCL- XL. Phosphorylation of this residue makes the interaction energetically 
unfavorable and preventing in this way BAD to interact with BCL- XL. 
In the research of Henshall et al. 2002, it was demonstrated that AKT mediated BAD 
phosphorylation limited seizure-induced cell death whereas cell death was increased 
when AKT- pathway was blocked with PI3- kinase inhibitor (LY294002). 
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Figure 11. Basic structures of pro-apoptotic BCL-2 family members (based on BH- 
motifs) (Adams and Cory 1998). 
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6.4.  PDK1 K465E- mutant mice 
 
PDK1 K465E mutant mice were developed in the laboratory of Dario R. Alessi 
(Bayascas et al. 2008). It is a specific knock-in point mutation where Lysine is 
mutated to glutamic acid. Mutation resides in the PH domain of PDK1 that specifically 
binds with phosphoinositides. Mutation prevents interaction with phosphoinositides 
and recruitment to the plasma membrane. This affects substantially PDK1s ability to 
phosphorylate AKT in Thr- 308. Phosphorylation of AKT is reduced in PDK1 K465E 
mutant mice but not completely disappeared. Mice expressing this mutation are 
viable but small and insulin resistant.  
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6.5.  Aims of the study 
 
Aim was to build up best conditions for detecting AKT substrate BAD in its 
phosphorylated state, more specifically when BAD Thr- 136 is phosphorylated. This 
was made by altering some reagents, concentrating protein samples by using 
immunoprecipitation and by using phospho- specific antibodies from two different 
suppliers. 
Another aim was to define whether Bad phosphorylation is affected or not in the 
PDK1 K465E neurons, and correlate that with the fact that cells survive well but do 
not differentiate similarly, e.g. shorter neurites of cortical neurons and aberrant 
axonal formation and growth in hippocampi (Zurashvili et al. 2013), as in the wild-
type animals. 
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7. Materials and methods 
 
7.1. Cell culture and stimulation 
 
Cells were cortical neurons mostly from wild type mice and those were used for 
building up the best conditions for detection of P- BAD136(Thr). In the end of the 
experiment were used cortical lysates also from PDK1 K465E- mutant mice. 
 
Cell culture 
To obtain embryonic primary cultures, pregnant female mouse was sacrificed at 
gestational stage E15 (15th day of pregnancy) counted from the appearance of the 
vaginal plug after mating. Both cerebral hemispheres were taken from the embryos 
and the rest of the body was saved for genotyping.  
Cells were dissociated first enzymatically by treating them with Solution 2 (Table 2) at 
37°C for 10 minutes. After 10 minutes solution 4 was added to stop the reaction. 
After centrifugation supernatant (mixture of Sol 2+ Sol 4) was discarded and solution 
3 added on top of the pellet and cells were dissociated mechanically by gentle 
pipetting using a fire-polished glass Pasteur pipette. Then solution was filtrated 
several times through nylon mesh and cells collected and added to solution 5. 
Gained cell- suspension was once again centrifuged and supernatant disgarded. 
After this pellet was resuspended with Culture Medium I (Table 3) and cells were 
counted. 
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Table 2: Solutions used in preparation of cell culture. 
Solution 1 Solution 2 Solution 3 Solution 4 Solution 5 
50 ml Krebs 
Ringer Buffer 
(KRB) 
10 ml Sol 1 10 ml Sol 1 84 ml Sol 1 5 ml Sol 1 
0,15 mg BSA 2,5 mg trypsin 
5,2 mg trypsin 
inhibitor 
1,6 ml Sol 3 
40µl MgSO4 
3,8% 
400µl MgSO4 
3,8% 
 100µl MgSO4 3,8%  6 µl CaCl2 1.2% 
  0,8 mg DNAse   
 
With the counted cell density in the solution (150 000 cells/ml), cells were plated onto 
poly-D-lysine (50 μg/ml) coated 24- well or 6- well plates. After 2 hour incubation 
medium was entirely replaced with Culture Medium II (Table 3). Cells were incubated 
at 37°C containing 5 % CO2 in normoxia. One half of the medium was changed for 
fresh medium (Culture Medium II) every 3 or 4 days. 
 
Table 3: Culture Mediums used in a cell culture. 
Culture Medium I Culture Medium II 
Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma Aldrich® D-5796) 
Neurobasal® (Gibco® 21103) 
 
10% Fetal Bovine Serum (Gibco®) 
B27® Serum- free supplement 50X 
(Gibco®, 17504) 
30 mM glucose 30 mM glucose 
2 mM L- glutamine 2 mM L- glutamine 
0,25 mg/ml penicillin/streptomycin 0.25 mg/ml penicillin/streptomycin 
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Starvation and stimulation 
 
Starvation or trophic factor deprivation was performed in order to activate apoptotic 
route in neurons (Zurashvili et al. 2013). It was performed at 5th- 6th day in vitro (DIV) 
by washing cells twice with serum-free DMEM and incubating them at 37°C for 4 
hours with serum-free Neurobasal (supplemented with 30 mM glucose, 2 mM L-
glutamine, and 0,25 mg/ml of penicillin/streptomycin). 
After 4 hours of starvation cells were stimulated with BDNF (Brain-derived 
neurotrophic factor) diluted in DMEM. With stimulation is investigated if BDNF can 
recover cell viability after trophic factor deprivation (Zurashvili et al. 2013). Different 
exposure times were used to investigate the biochemical pathway activation. Times 
were 0 (control), 1, 5, 15 and 30 minutes of stimulation with BDNF. After defined time 
reaction was stopped by aspirating and discarding BDNF-DMEM solution and adding 
Lysis Buffer (Table 4) on top of the stimulated cells. Cell lysates were stored in 
eppendorf-tubes at -20°C.   
 
Table 4: Content of Lysis Buffer 
Tris-HCl pH 7,5 50 mM 
EGTA 1 mM 
EDTA 1 mM 
sodium orthovanadate 1 mM 
sodium fluoride 50 mM 
sodium pyrophosphate 5 mM 
sodium beta glicerophosphate 10 mM 
sucrose 0,27 M 
Triton X- 100 1% (m/V) 
2-mercaptoethanol 0,1 % (V/V) 
Proteinase inhibitor mixture 1% (V/V) 
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7.2. The Bradford assay 
 
Method to measure quantitatively protein concentration in a solution that is based on 
protein binding with a dye is called Bradford assay (Boyer 2012 p.67- 69). Assay was 
done to all proteins used in experiments to ensure equal loading of each sample.  
From each different lysate was prepared two parallel samples and their absorbance 
was measured with spectrophotometer. Measuring was executed immediately after 
adding the dye, Coomassie Brilliant Blue to the cuvette, by using wavelength 595nm. 
Also three blanks were measured and their average absorbance counted in order to 
subtract it from actual samples. Altered absorbance caused by protein binding with 
the dye was recorded, averages calculated and blank average absorbance 
subtracted. Then values were calculated as concentrations by using the standard 
curve prepared from bovine serum albumin (BSA). 
 
7.3. Immunoprecipitation 
 
Immunoprecipitation was performed in order to pull- down protein BAD from a cell 
lysate. Antibody that was used in the precipitation was Total- BAD mouse 
monoclonal antibody (table 10 primary antibodies used). The concentration was 1 or 
2 µg of antibody per 10µl of A- Sepharose beads. When preparing the beads, an 
excess of 10µl was always added to the volume needed due to difficulties faced 
when pipetting the beads.  
First step was washing the beads with wash buffer, centrifugation at 4°C for 1 minute, 
and aspiration of the buffer. This was repeated two times more. In the last aspiration 
approximately 50µl of wash buffer was left in the eppendorf. Nonionic detergent 
Triton X-100 and low salt concentration (150 mM NaCl) was used in the wash buffer 
(Table 5). Wash buffer was prepared by adding salt (NaCl) to Lysis buffer that was 
made up (content in table 4). 
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Table 5: Wash Buffer 
Lysis Buffer 100 ml 
NaCl 2,9 g 
 
After washing the beads, antibody was pipetted into the eppendorf and it was 
incubated at least 30 minutes in a roller at 4°C in order to make antibody attach to 
the beads. During the incubation of beads with the antibody, protein samples were 
prepared. Amounts of proteins used for immunoprecipitation were explicitly larger 
than in Western Blot (see chapter 7.4.), varying between 50 up to 250µg. After 30 
minutes of incubation, bead- antibody mixture was washed three times with wash 
buffer the same way than earlier. Then 10µl of washed bead- antibody mixture was 
pipetted to each tube containing proteins and they were incubated at least for 1 hour 
in a roller at 4°C. In this step protein desired to pull down was attached to the bead- 
antibody- complex.  
After incubation tubes were centrifuged and supernatants were carefully pipetted to 
new labeled eppendorfs and saved. Pellets were washed three times with wash 
buffer the same way than earlier. In the last aspiration all of the liquid was removed 
and 40µl of wash buffer+ 10µl of loading buffer without β- mercaptoethanol was 
added and samples were ready to load on the polyacrylamide-gel (see chapter 
7.5.1.). As a control was used bead- antibody mixture in a wash buffer. This was 
made to ensure that antibody is attached to the beads (that beads are working 
correctly) and no free antibody remains in the wash buffer. 
 
7.4. Preparing the samples for Western Blot 
 
By using calculated concentrations (see chapter 7.2.), volumes of protein lysates 
needed for loading were calculated so that the amount of loaded protein were equal 
in each well. If needed, water was added to gain wanted volume. Amounts per 
loading varied between 10- 40µl (amounts of proteins varied from 12,5µg up to 60µg) 
in separate Western Blots due to shortage of lysates. To each sample was added 
loading buffer with ratio 1:5 that contained bromophenol blue and β-mercaptoethanol 
in order to monitor the progress of electrophoresis and to break the disulfide bonds, 
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respectively. As mentioned in the previous chapter 7.3., to the proteins that were 
immunoprecipitated with anti- BAD β- mercaptoethanol was not added because of its 
ability to denature the antibody and distract immunoprecipitation (Simpson et al. 
2009). 
To break the three dimensional structure of a protein, surrounding conditions for the 
protein has to be made unfavorable (Campbell and Farrell 2006 p.99- 101). It is also 
called denaturing and it can be done by heating, altering pH or with detergents.  
Methods that was used in this experiment was added sodium dodecyl sulfate (SDS) 
to the polyacrylamide gel (Berg et al.2002 p.84, Campbell and Farrell 2006 p.101) 
and by heating samples just before loading.  
 
7.5. Western blot 
 
When it is necessary to detect small amount of a certain protein from a mixture of 
many proteins (e.g. cell lysate), immunoassay technique called Western Blot is a 
good procedure to use (Berg et al. 2002 p.103, Lodish et al. 2008 p.98, Boyer 2012 
p.194). It is a multistep procedure, a combination of techniques that makes possible 
to separate proteins and detect and observe a protein of interest (Lodish et al. 2008 
p.98). It is a similar technique as Southern Blotting but instead of transferring DNA, 
Western Blot is designed to work with proteins (Berg et al. 2002 p.146, Campbell and 
Farrel 2006 p.358). The procedure consists of SDS- polyacrylamide- gel 
electrophoresis (SDS- PAGE), electroblotting and antibody-antigen based detection 
of proteins of interest (Berg et al. 2002 p.103, Campbell and Farrel 2006 p.121, 
Boyer 2012 p.194- 195). 
 
7.5.1. SDS- PAGE 
 
In order to fractionate proteins, they are forced to migrate through polyacrylamide gel 
by electric field (Berg et al. 2002 p.84, Boyer 2012 p.194). Prefix SDS (sodium 
dodecyl sulfate) stand for denaturing conditions (see chapter 7.4.). Movement of 
proteins is based on their molecular sizes and it determines their separation. At the 
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end of the electrophoresis small proteins are at the bottom, whereas large proteins 
stay near to the place of loading (Berg et al. 2002 p.84-85, Campbell and Farrel 2006 
p.121). 
Used concentrations of gels in this experiment were either 7,5% or 12%, where 
concentration of 12% provided bigger resistance for proteins. Gels were prepared 
according to the table 6, in such a way that the running gel was at the bottom and 
stacking gel including the loading wells were on top of that. Equal amount of lysate 
varying between 10µl- 40µl (in separate gels) were loaded in the wells and 
fractionated with electric current of 160V approximately for one and a half hour 
(depending of the density of the gel; 7,5% gel completed in lesser time). To be able 
to identify the different molecular weights afterwards, protein marker Precision Plus 
ProteinTM Standard (Bio Rad Laboratories, Inc) was loaded also in the acrylamide, 
usually in the outermost well/ wells. Electrophoresis happened in a buffer, which 
content is shown in table 7. 
 
Table 6: Gels for Western Blot 
For 2 gels Stacking Running 
SOLUTION 
 
7,50 % 12 % 
30% Acrylamide/ 0,8% Bis solution (37,5:1) (Merck, 
Germany) 
850 μL 5 mL 8 mL 
H20 (distilled) 3,8 mL 10 mL 7 mL 
1,5 M Tris- Base (pH 8,8) (Sigma, USA) ----- 5,0 mL 5,0 mL 
0,5 M Tris- Base (pH 6,8) (Sigma-USA) 325 μL --- --- 
20 % SDS (Sigma, Japan) 25 μL 0,25 mL 0,25 mL 
10 % APS (Sigma, USA) 50 μL 150 μL 150 μL 
TEMED (Sigma, China) 5 μL 30 μL 30 μL 
 
Table 7: SDS- electrophoresis buffer 
Tris-Base (Sigma, USA) 3,0 g 
Glycine (Sigma, South Korea) 14,4 g 
SDS (Sigma, Japan) 1,0 g 
H2O (distilled) ad 1,0 l 
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7.5.2. Electroblotting 
 
After proteins are fractionated by electrophoresis they are still deeply embedded in 
the polyacrylamide gel (Berg et al. 2002 p.84, Campbell and Farrel 2006 p.358, 
Lodish et al. 2008 p.98, Boyer 2012 p.194). In order to get proteins more accessible 
they have to be transferred (blotted) to a support matrix that allows working with 
strongly bound and immobilized proteins. Different types of support matrixes exist, 
but in this experiment was used nitrocellulose membrane.  
For the transfer a cassette is assembled according to the figure 12 so that the electric 
current transfers proteins from the polyacrylamide gel onto the membrane. Order in 
the cassette is sponge, filter paper x2, gel, membrane, filter paper x2 and sponge. 
Casette is placed between platinum electrodes and electric current is then passed 
through the gel and proteins electrophorese from the gel to the membrane. Like 
electrophoresis, electroblotting happens also in a buffer solution (table 8), at 100V for 
90 minutes and temperature lowered near 4°C with ice.  
 
 
 
 
 
 
 
 
 
 
Table 8. Transfer (blotting) buffer 
Tris- Base (Sigma, USA) 3,0 g 
Glycine (Sigma, South Korea) 15,0 g 
Methanol 200 ml 
H2O (distilled) ad 1,0 l 
After preparation cooled in a freezer to mitigate produced heat during the transfer. 
 
Figure 12. Arrangement in the transfer cassette (sandwich). 
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7.5.3. Antibody-antigen based detection 
 
Immunodetection includes following steps: blocking the membrane, incubation with 
primary antibody, incubation with secondary antibody, adding chemiluminescent 
substrate and exposure and develop of a film (Berg et al. 2002 p.103, Lodish et al. 
2008 p.98, Boyer 2012 p.195-197).  
Blocking the membrane with protein solution ensures that the primary antibody 
doesn't interfere with other than blotted proteins. In this research was used either 
casein (major protein in milk) or BSA (bovine serum albumin) in TBS-Tween. 
Blocking took place at room temperature for 45 minutes. 
After blocking, the membrane was incubated with specific primary antibody that binds 
to desired proteins. Used concentration of primary antibody was usually 1:1000, but 
in some cases higher concentrations were used; 1:500, 1:200 or even 1:100. Primary 
antibodies were diluted in 0,5% or 5% BSA depending whether antibody was 
phospho or total, respectively. Incubation was performed at 4°C usually for 12- 18 
hours or more. After washing the membrane from excess of primary antibody (3x 10 
minutes with TBS- Tween) the secondary antibody (Table 11) conjugated with HRP 
(horseradish peroxidase) was directed against the primary antibody to interact with it. 
This took place at room temperature for 50 minutes. Used concentrations with 
secondary antibody were 1:2500 in 5% milk. Washes were repeated to remove 
excess of secondary antibody as well. All incubations and washes were performed in 
a horizontal roller.  
Enzyme that is conjugated with secondary antibody (HRP) catalyzes the reaction that 
produces light signal. Composition of mixture that was used to produce 
chemiluminescent is seen in table 9. After mixing ECL1 and 2 together, the reaction 
start to happen immediately so the incubation with the membrane had to be short 
(was 1 minute) not to lose adequate light signal. Right after this film (Fuji Film Super 
RX) was exposed to light producing membranes in the darkroom and then 
developed.  
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Table 9: Composition of ECL1 and 2 (enhanced chemiluminescence). Mixed together 
just before incubating the membranes. 
ECL 1  
1 M Tris HCl (pH 8,5) 200 µl 
0,5M Luminol 10 µl 
79.2 mM p-Coumaric Acid 10 µl 
H2O (distilled) ad 2 ml 
  
ECL 2  
1 M Tris HCl pH 8,5 200 µl 
8.8 M Hydrogen Peroxide (H2O2) 1,3 µl 
H2O (distilled) ad 2 ml 
 
Table 10: Primary antibodies used 
Antibody Host Provider Cataloque 
number 
P-BAD S112 Rabbit Cell Signaling Technology 5284 
P-BAD S136 Rabbit Cell Signaling Technology 5286 
P-BAD S155 Rabbit Cell Signaling Technology 9297 
Total BAD Rabbit Cell Signaling Technology 9239 
P-BAD S136 Rabbit Cell Signaling Technology 9295S 
Total BAD Mouse BS Biosciences 36919 
P-AKT T308 Rabbit Cell Signaling Technology 9275 
P-AKT S473 Rabbit Cell Signaling Technology 9271 
Total AKT  Sheep Dario R. Alessi/ University of 
Dundee 
 
 
 
Table 11: Secondary antibodies used 
Antibody Host Provider Cataloque 
number 
Anti-Rabbit HRP-conjugated Goat Thermo Scientific 31460 
Anti-Mouse HRP-conjugated Goat Thermo Scientific 31430 
Anti-Sheep HRP-conjugated Rabbit Thermo Scientific 31480 
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8. Results and discussion 
 
8.1. Effect of immunoprecipitation 
 
 BDNF-stimulated lysates 
0min 5min 15min 30min 
 
P-BAD (S136) 
 
 
BAD (total) 
 
 
Figure 13. Detecting P-BAD(S136) and BAD(total) from cortical cell lysates from wild 
type mice stimulated with BDNF at  different timepoints. 
 
On one of the first experiments was examined if BAD could be detected from regular 
cortical cell lysates (from wild type mice). As can be seen in figure 13 P- BAD (S136) 
cannot be detected but BAD (total) can, although weakly. From this result was 
concluded that protein concentration has to be higher (e.g. 50- 250µg instead of 
normal loading amount of 10- 25µg) to be able to detect P-BAD(S136) and also get 
stronger and more reliable signal from BAD(total). 
 
 
 
 
 
 
 
 
BDNF-stimulated lysates 
0min 5min 15min 30min * 
 
P-BAD (S136) 
 
 
P-BAD (S112) 
 
Figure 14. Detection of phosphorylated BAD at residues S136 and S112 in 
immunoprecipitated BDNF-stimulated cortical cell lysates. Control is marked as *, 
which consist of bead-antibody complex in a wash buffer. 
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After lysates were concentrated by immunoprecipitation, detection of P-BAD136 and 
P-BAD112 succeeded (figure 14). This finding supported conclusion that cortical cell 
lysates has to be concentrated in order to detect BAD and especially its 
phosphorylated states and it is recommended that at least 15 min incubation will be 
used to activate the process by BDNF. 
 
 
Figure 15. Saved supernatant was used in the experiment in order to detect how well 
immunoprecipitation succeeded (see chapter 7.3.).  
 
Figure 15 show difference of BAD(total) detection between immunoprecipitated 
(concentrated) lysates and supernatant gained from immunoprecipitation. Some 
protein is still left with samples in timepoints 15 and 30 min. Especially sample in 
timepoint 15 min correlates with weaker detection of P-BAD (S136) and P-BAD 
(S112) in timepoint 15 min in figure 14. 
 
 
Figure 16. Detection of AKT(total).  
 
 Total lysates Supernatant 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
 
BAD (total) 
 
 Total lysates Supernatant 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
 
AKT (total) 
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Figure 16 represents AKT as a control of loading. Results are from the same Western 
blot than results in figure 15, although this is the upper part of the same membrane. 
Detection should be equal in each timepoint. From the figure can be concluded that 
the loading is a bit uneven. 
 Total lysates Supernatant 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
 
BAD (total) 
 
 
Figure 17: Another experiment presenting the difference of BAD(total) detection 
between immunoprecipitated (concentrated) lysates and supernatant gained from 
immunoprecipitation where most of the protein is gone because of the attachment to 
the BAD- antibody- bead- complex. 
 
As can be seen from the figure 17 immunoprecipitation succeeded better with 
samples at timepoints 0 and 5 minutes than in 15 and 30 minutes. Some protein is 
still left in the supernatant at timepoints 15 and 30 minutes. 
 
 
Figure 18: Upper part of the same membrane which was used to detect BAD in 
Figure 17, was treated with AKT(total) antibody to get control of loading. 
 
Figure 18 shows that detection of AKT(total) is also a bit weaker in supernatant at 
timepoints 0 and 5 minutes than in total lysate samples. This should not happen 
because immunoprecipitation with BAD(total)- antibody cannot affect to the amount 
of AKT. This weaker signal can be explained by inaccurate loading of samples. 
 Total lysates Supernatant 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
 
AKT (total) 
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However, loading is more accurate than in figure 16, especially with loading of total 
lysates. 
 
8.2. Antibodies from different suppliers 
 
 BDNF-stimulated lysates 
0min 5min 15min 30min 
 
P-BAD (S112) (5284) 
 
 
P-BAD (S136) (5286) 
 
 
BAD (total) (9239) 
 
 
P-AKT (S473)  
 
 
Figure 19: Detection with antibodies from Cell Signalling Technology. P- AKT(S473) 
as a control. 
 
P-BAD S112 (5284), P-BAD S136 (5286) and Total BAD (9239) antibodies from Cell 
Signalling Technology (table 10 on page 51) were tested with cortical cell lysates 
from wild type mouse without immunoprecipitation. P-AKT (S473) was used as a 
control. In the figure 19 cannot be seen signals from P-BAD (S112), P-BAD (S136) or 
BAD (total). Some signals were detected, but molecular weight did not match to the 
BAD (23kDa). However, signal produced by P-AKT (S473) is strong and it 
demonstrates that phosphorylation of AKT is not impaired in these neurons. 
Based on the experiments was discovered that the ability of Total BAD #9239 (Cell 
Signalling Technology) to pull- down BAD from lysates in immunoprecipitation was 
weaker than with Total BAD (BS Bioscience) (results not shown). Because of this 
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observation all later immunoprecipitations were performed with Total BAD (BS 
Bioscience).  
It was also found that P-BAD (S136) #9295S (Cell Signalling Technology) works 
better than P-BAD (S136) #5286 (Cell Signalling Technology). P-BAD (S136) #5286 
was also tested with concentrated lysates (results not shown) but no detection was 
observed with this specific anti- body. In all later experiments was used #9295S to 
detect phosphorylation of BAD(S136).  
 
8.3. PDK1 K465E neurons 
Figure 20. Phosphorylation of BAD residues 136 and 112, and same membranes 
treated afterwards with total-BAD antibody. 
 
Cortical cell lysates gained from wild type and mutant mice were first 
immunoprecipitated according to the earlier findings that lysates has to be 
concentrated in order to detect P-BAD 136 and 112. As figure 20 shows detection of 
 Wild type Mutant  (K465E) 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
 
P-BAD 
(S136) 
 
 
BAD (total) 
 
 
P-BAD 
(S112) 
 
 
BAD (total) 
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phosphorylation succeeded. Even though totals barely can be seen (film got wet) 
some signal can be detected and that supports reliability of P- BAD(112 and 136) 
signals. 
It seems that phosphorylation of S112 and S136 is weaker in mutant lysates 
compared to wild type. With both lysates phosphorylation of S112 seems to be 
strongest at timepoint 15 min. Detection of S136 is strongest at 30 min with wild type 
and at 15 min with mutant. Possibly 15 minute exposure in BDNF is optimal time 
after starvation to activate the biochemical pathway in mutant lysates. 
 
 
Figure 21. Loading controls (AKTs) and results of succeeding of the 
immunoprecipitation. 
 
As can be seen from the figure 21 (based on AKT(total)s) loadings are quite even. 
Some wells have bigger amount of lysate and that correlates with stronger detection 
of corresponding P- AKT(308). When comparing detection of phosphorylated 
 Total lysates Supernatant 
BDNF-stimulation time 
0min 5min 15min 30min 0min 5min 15min 30min * 
P-AKT 
(308) WT 
 
AKT (total) 
WT 
 
P- AKT 
(308) MT 
 
AKT (total) 
MT 
 
BAD (total) 
WT 
 
BAD (total) 
MT 
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AKT(308)s to the corresponding AKT(total)s, it seems that detection is a bit stronger 
in WT than in MT lysates. 
When observing immunoprecipitated lysates, some amount of protein is still left in the 
supernatant. With WT in timepoints 5, 15 and 30 min signal is especially strong. 
When comparing these timepoints to the figure 20 it does not seem likely that 
immunoprecipitation failed because signals are so strong. Explanation may be the 
saturation of beads.  
With MT in timepoint 5 min some protein is left in supernatant (figure 21) and it 
correlates with weaker signal of P- BAD(S136) and P- BAD(S112) (figure 20). 
Despite this, can be concluded that immunoprecipitation succeeded quite well 
because lysate seems to be rich of protein. 
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9. Conclusions 
 
Even though the lysates were immunoprecipitated, protein was hard to detect and 
signals appeared faintly. Larger amount of antibody was used when concentrations 
had to be elevated in order to detect P-BAD. This kind of research requires large 
amount of resources. Generating specific mouse genotype and establishing 
embryonic primary cultures requires a lot of time and effort.  Also as a method, 
Western Blot is a bit inaccurate because it was based only on a visual estimate result 
from a lack of equipment. 
It was also observed that as a protein, BAD is very small and hard to detect 
especially on its phosphorylated state. Concentration of protein was very low at 
cortical lysates and it was noticed that protein degrade easily when adding β- 
mercaptoethanol. From these observations can be concluded that BAD is a delicate 
protein to work with and it requires plenty of skills and precision from the worker. 
Because of the lack of time and shortage of PDK1 K465E- lysates, only two parallel 
experiments were performed with mutated neurons. Hence, more experiments have 
to be conducted to get more reliable data. 
Scientific value is also affected by the precision of the worker. Results indicate that 
some stages would have required more precision, for example there are variations in 
loadings. Again, more repeats would reduce this defect. 
In the base of this research it seems that PDK1 K465E- mutation has effect in 
phosphorylation of pro- apoptotic BAD. Phosphorylation of BAD Ser- 136 was weaker 
in mutant than in wild type. This indicates that when AKT activation is impaired in 
consequence of its hypophosphorylation, it decreases also phosphorylation of BAD 
at Ser-136. This would mean that BAD attaches to BCL- 2 or BCL- XL and in this way 
causes release of pro- apoptotic BAX that further leads to apoptosis.  
In the research of Rokhlin et al. (2004) was investigated the effect of inhibition of 
PDK1/AKT pathway on phosphorylation of BAD Ser- 136 in prostatic carcinoma cell 
lines. Results indicated that when PDK1/AKT pathway activation was impaired,  
phosphorylation of BAD Ser- 136 was subsequently reduced. Although inhibition 
lowered phosphorylation of PDK1-Ser241 and did affect in PH-domain in no manner, 
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it supports the fact that PDK1 has to be fully activated in order to phosphorylate AKT-
Thr308 and subsequently AKT to phosphorylate BAD Ser-136. This strongly supports 
the importance of PDK1/AKT pathway on inhibiting apoptotic cascade via 
phosphorylation of pro-apoptotic BAD. 
Phosphorylation of BAD Ser- 136 is known to improve docking with 14-3-3 proteins 
and as well promote phosphorylation of Ser- 155 which is important step to inhibit 
formation of heterodimer with BCL- XL. If phosphorylation is completely impaired, it 
would be improbable that mice would be viable in birth. 
Previous data from experiments done with neurons from PDK1 K465E- mutant mice 
indicated that mice were viable, only smaller and insulin resistant (Zurashvili 2013). 
Also phosphorylation and inhibition of other apoptotic substrates of AKT, such as 
GSK3 or FOXO were shown to be normal and their inhibition was not decreased. 
It is possible that even if AKT function is impaired, it can still phosphorylate BAD at 
Ser-136 at some level or BAD is phosphorylated by some other kinase. If BAD 
phosphorylation indeed is impaired in PDK1 K465E- neurons could that be the 
causative factor to the small size of the mice if other substrates are phosphorylated 
normally? Further investigation is needed with PDK1 K465E-neurons to demonstrate 
whether BAD Ser- 136 phosphorylation is affected or not. 
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